

Accession	Protein	Gene	Species	Protein length (aa)	Gene length (bp)	Accession	Protein	Gene	Species	Protein length (aa)	Gene length (bp)
AAE09440	standard; Protein; 130 AA			130		AAE09440	standard; Protein; 130 AA			130	
XX	AAE09440:					XX	AAE09440:				
AC	19-NOV-2001 (first entry)					AC	19-NOV-2001 (first entry)				
XX	Human sbhgCta protein.					XX	Human sbhgCta protein.				
DE	Human; Alzheimer's disease; amyloid					DE	Human; Alzheimer's disease; amyloid				
XX	ALS; Zollinger-Ellison syndrome; inflammation; hematopoietic disease					XX	ALS; Zollinger-Ellison syndrome; inflammation; hematopoietic disease				
KW	anorexia; depression; cardiovascular					KW	anorexia; depression; cardiovascular				
KW	memory alteration; migraine; stroke					KW	memory alteration; migraine; stroke				
KW	sexual disorder; growth abnormality					KW	sexual disorder; growth abnormality				
KW	rheumatoid arthritis; cataractogenesis					KW	rheumatoid arthritis; cataractogenesis				
KW	cerebral ischaemia; cirrhosis; Huntington's disease					KW	cerebral ischaemia; cirrhosis; Huntington's disease				
KW	hypercholesterolaemia; headache; diabetes mellitus; glomerulonephritis					KW	hypercholesterolaemia; headache; diabetes mellitus; glomerulonephritis				
KW	cancer; vaccine; gene therapy; sbhg					KW	cancer; vaccine; gene therapy; sbhg				
XX						XX					
OS	Homo sapiens.					OS	Homo sapiens.				
XX						XX					
PN	W0200160850-A1.					PN	W0200160850-A1.				
XX						XX					
PD	23-AUG-2001.					PD	23-AUG-2001.				
XX						XX					
PF	14-FEB-2001; 2001WO-US04703.					PF	14-FEB-2001; 2001WO-US04703.				
XX						XX					
PR	14-FEB-2000; 2000US-0182172.					PR	14-FEB-2000; 2000US-0182172.				
ER	29-FEB-2000; 2000US-0186084.					ER	29-FEB-2000; 2000US-0186084.				
PR	18-APR-2000; 2000US-0198583.					PR	18-APR-2000; 2000US-0198583.				
PR	04-OCT-2000; 2000US-0237963.					PR	04-OCT-2000; 2000US-0237963.				

XX (SMIK) SMITHKLINE BEECHAM CORP.
 PA (SMIK) SMITHKLINE BEECHAM PLC.
 XX
 PI Agarwal P, Kabnick KS, Murdoch PR, Rizvi SK, Smith RF, Xiang Z;
 XX WPI, 2001-536566/59.
 DR N-PSDB; AADI6347.
 XX
 PT New secreted and membrane associated polypeptides for treating
 PT Alzheimer's disease, psoriasis, cancer, enterocolitis, sleep and sexual
 PT disorders, stroke, and asthma -
 PS
 PS Claim 1: Page 58-59; 94pp; English.
 CC The present sequence is a human sbpHc7a protein,
 CC a secreted protein of the invention.
 CC The invention relates to secreted and membrane associated polypeptides
 CC and nucleic acid molecules encoding such polypeptides. Sequences of the
 CC invention are useful for treating diseases such as Alzheimer's disease,
 CC amyotrophic lateral sclerosis (ALS), Zollinger-Ellison syndrome, diseases
 CC of the immune system, haematopoietic disease, inflammation, anxiety,
 CC schizophrenia, feeding disorders, anorexia, depression, social, sexual
 CC and rewarded behaviour, cardiovascular disease, sleep disorder, learning
 CC and memory alteration and altered immune response, seizure, migraine,
 CC cancer, stroke, asthma, neuropathy, aging, sexual disorders, treatment
 CC of transsexuals, growth abnormalities, obesity, infections, autoimmune
 CC diseases (e.g. rheumatoid arthritis), cataractogenesis, angiogenesis,
 CC disorders associated with healthy maintenance of gastric mucosa and
 CC repair of acute and chronic mucosal lesion, lung carcinoma, cerebral
 CC ischemia, atherosclerosis, cirrhosis, Huntington's disease, headache,
 CC amnesia, multiple sclerosis, Hodgson's disease, dilated cardiomyopathy,
 CC congestive heart failure, cardiac arrhythmias, hypercholesterolaemia,
 CC viral and non-viral hepatitis, type I and type II diabetes mellitus,
 CC glomerulonephritis, renovascular hypertension, hypoglycaemia, periodic
 CC paralyseis, tendinitis and malignant hyperthermia. Polypeptides of the
 CC invention are used to identify membrane bound and soluble receptors.
 CC They are also useful as vaccines for inducing an immunological response
 CC in a mammal. Polynucleotides of the invention are used in gene therapy.
 CC They are also valuable for chromosome localisation studies and tissue
 CC expression studies.
 CC
 XX
 SO Sequence 130 AA:
 Query Match 100.0%; Score 722; DB 22; Length 130;
 Best Local Similarity 100.0%; Pred. No. 9,1e-70;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKLAFLFGPMALLLAGYGCYVLAGSSGNLRTFVGCAVREFTFLAKKPGCGRLRTTDDAC 60
 Db 1 MKLAFLFGPMALLLAGYGCYVLAGSSGNLRTFVGCAVREFTFLAKKPGCGRLRTTDDAC 60
 QY 61 WGRCEWKEKPILEPPYTEAHHRVCTYNETKQVTKLPNCAPGVDPFTYTPVAIRCDGAC 120
 Db 61 WGRCEWKEKPILEPPYTEAHHRVCTYNETKQVTKLPNCAPGVDPFTYTPVAIRCDGAC 120
 QY 121 STATTECETI 130
 Db 121 STATTECETI 130
 RESULT 2
 ID AAG63211 standard; Protein; 130 AA.
 AC AAG63211;
 XX
 DT 01-OCT-2001 (first entry)
 XX
 DE Amino acid sequence of a human cystine knot polypeptide.
 XX
 KM Cystine knot polypeptide; follicular arrest; recruitment modulator;
 KM fertility-related disorder; contraception; menopause; contraceptive;

KM follicle growth.
 XX
 OS Homo sapiens.
 XX
 PN WO200153346-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 17-JAN-2001; 2001MO-EP00570.
 XX
 PR 18-JAN-2000; 2000EP-0200185.
 XX
 PA (ALKU) AKZO NOBEL NV.
 XX
 PI Mosselman S, Spek Van Der PJ;
 XX WPI, 2001-476102/51.
 DR N-PSDB; AAA42567.
 XX
 PT New DNA sequences, useful for coding or producing cystine knot
 PT polypeptides, which are useful in preparing a pharmaceutical for
 PT fertility-related disorders or contraception, and for controlling
 PT follicular arrest and recruitment -
 PS
 PS Example 1: Page 23-24; 29pp; English.
 CC The present sequence represents a human cystine knot polypeptide. The
 CC polypeptide is a follicular arrest and recruitment modulator. Cystine
 CC knot polypeptides are useful in preparing a pharmaceutical for
 CC fertility-related disorders or in contraception. The polypeptide is
 CC particularly useful for controlling follicular arrest and recruitment.
 CC Inhibition of recruitment can be used to delay (premature) menopause or
 CC as a contraceptive. The polypeptide is also useful for in vitro
 CC maturation and growth of follicles, e.g. from frozen ovarian tissue.
 CC
 XX
 SO Sequence 130 AA:
 Query Match 100.0%; Score 722; DB 22; Length 130;
 Best Local Similarity 100.0%; Pred. No. 9,1e-70;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKLAFLFGPMALLLAGYGCYVLAGSSGNLRTFVGCAVREFTFLAKKPGCGRLRTTDDAC 60
 Db 1 MKLAFLFGPMALLLAGYGCYVLAGSSGNLRTFVGCAVREFTFLAKKPGCGRLRTTDDAC 60
 QY 61 WGRCEWKEKPILEPPYTEAHHRVCTYNETKQVTKLPNCAPGVDPFTYTPVAIRCDGAC 120
 Db 61 WGRCEWKEKPILEPPYTEAHHRVCTYNETKQVTKLPNCAPGVDPFTYTPVAIRCDGAC 120
 QY 121 STATTECETI 130
 Db 121 STATTECETI 130
 RESULT 3
 ID AAG64064 standard; protein; 130 AA.
 AC AAG64064;
 XX
 DT 17-SEP-2001 (first entry)
 XX
 DE Human anterior pituitary hormone-related polypeptide.
 XX
 KM Human; anterior pituitary hormone; hypertension; autoimmune disease;
 KM heart failure.
 XX
 OS Homo sapiens.
 XX
 PN WO200144475-A1.
 XX
 PD 21-JUN-2001.

```

PF 15-DEC-2000; 2000WO-JP08896.
XX
PR 17-DEC-1999; 99JP-0358707.
PR 18-FEB-2000; 2000JP-0046825.
XX
PA (TAKE ) TAKEDA CHEM IND LTD.
XX
PI Hinuma S, Fukusumi S, Fujii R, Hosoya M;
XX
DR WPI: 2001-408485/43.
DR N-PSDB; AAF46586.
XX
PT Polypeptides for treatment of hypertension, autoimmune disease and
PT heart failure -
XX
PS Claim 1; Fig 2; 107pp; Japanese.
XX
CC The invention relates to a novel polypeptide comprising a fully defined
CC 130 amino acid sequence given in the specification and its amides,
CC esters and salts. The polypeptide has anterior pituitary hormone-related
CC activity. It is useful for the treatment of hypertension, autoimmune
CC diseases and heart failure. The screening method and kit also
CC provided in the invention are useful for identifying new substances
CC for treating and preventing these diseases. The present sequence is
CC the polypeptide of the invention.
XX
SQ Sequence 130 AA;
Query Match 100.0%; Score 722; DB 22; Length 130;
Best Local Similarity 100.0%; Pred. No. 9.1e-70;
Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MKLAFLEGPMAILLLAGYGVLAGSSGNLRFVGCAREFTFLAKKPGCRGLRTTDC 60
DB 1 MKLAFLEGPMAILLLAGYGVLAGSSGNLRFVGCAREFTFLAKKPGCRGLRTTDC 60
OY 61 WGRCEWKEPILPEPYIEAHNRVCYNETKQVTVKLPNCAPGVDPFYTPVAIRDCGAC 120
DB 61 WGRCEWKEPILPEPYIEAHNRVCYNETKQVTVKLPNCAPGVDPFYTPVAIRDCGAC 120
OY 121 STATTCEETI 130
DB 121 STATTCEETI 130
OY 121 STATTCEETI 130
DB 121 STATTCEETI 130
RESULT 4
AAB84998 standard; Protein; 230 AA.
XX
AC AAB84998;
XX
DT 06-AUG-2001 (first entry)
XX
DE Human novel gonadotropin (NOVGON) protein.
XX
KW NOVG: transmembrane protein; NOVTRAN; neuromedin peptide; NOVNEUR;
KW gonadotropin-like protein; NOVGON; interleukin-1; NOVINTRA; human;
KW cytosolic; neuroprotective; reproductive; antiinflammatory; cancer;
KW antibacterial; cerebroprotective; antidiabetic; antiarthritic;
KW antiallergic; antiallergic.
XX
OS Homo sapiens.
XX
PN WO200140291-A2.
XX
PD 07-JUN-2001.
XX
PF 06-DEC-2000; 2000WO-US33029.
XX
PR 06-DEC-1999; 99US-0169056.
PR 09-DEC-1999; 99US-0169866.
PR 09-DEC-1999; 99US-0169886.
PR 10-DEC-1999; 99US-0170252.

```

```

PR 12-JAN-2000; 2000US-0175740.
PR 05-DEC-2000; 2000US-0170252.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Burgess CE, Prayaga SK, Shimkets RA, Rastelli L, Zerhusen BD;
PI Mezes PS;
XX
DR WPI: 2001-374790/39.
DR N-PSDB; AAF83867.
XX
PT Novel isolated human transmembrane, neuromedin peptide
PT gonadotropin-like protein and interleukin-1 receptor antagonist
PT proteins, useful for treating cancer, immune response disorder,
PT metabolic function disorders -
XX
PS Claim 1; Fig 6B; 138pp; English.
XX
CC The invention provides novel polypeptides (NOVG) selected from human
CC transmembrane protein (NOVTRAN), neuromedin peptide (NOVNEUR),
CC gonadotropin-like protein (NOVGON) and two interleukin-1 receptor
CC antagonist proteins (NOVINTRA A and B). The invention also provides
CC methods in which a NOVG polypeptide, polynucleotide and antibody are
CC used in the detection, prevention and treatment of a broad range of
CC pathological states. NOVTRAN can be used to treat is a cell signalling
CC disorder such as cancer, immune response disorder, hematopoietic
CC disorder, neurodegenerative disorder. NOVNEUR can be used to treat
CC endocrine disorder, muscle disorder, neurologic disorder, cancers of
CC central nervous system, breast, colon, ovary, kidney, prostate and
CC thyroid. NOVGON can be used to treat reproductive development disorder,
CC metabolic function disorder and melanoma. NOVINTRA A and B can be used
CC to treat bone metabolism or structure disorder, inflammatory response
CC disorder, immune regulation disorder, septic shock, stroke, diabetes,
CC arthritis and cancer. The present sequence represents the NOVGON
CC polypeptide.
XX
SQ Sequence 230 AA;
Query Match 96.8%; Score 699; DB 22; Length 230;
Best Local Similarity 100.0%; Pred. No. 5.2e-67;
Matches 126; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MKLAFLEGPMAILLLAGYGVLAGSSGNLRFVGCAREFTFLAKKPGCRGLRTTDC 60
DB 1 MKLAFLEGPMAILLLAGYGVLAGSSGNLRFVGCAREFTFLAKKPGCRGLRTTDC 60
OY 61 WGRCEWKEPILPEPYIEAHNRVCYNETKQVTVKLPNCAPGVDPFYTPVAIRDCGAC 120
DB 61 WGRCEWKEPILPEPYIEAHNRVCYNETKQVTVKLPNCAPGVDPFYTPVAIRDCGAC 120
OY 121 STATTCE 126
DB 121 STATTCE 126
RESULT 5
AAG64067
ID AAG64067 standard; Protein; 129 AA.
XX
AC AAG64067;
XX
DT 17-SEP-2001 (first entry)
XX
DE Rat anterior pituitary hormone-related polypeptide #1.
XX
KW Rat; anterior pituitary hormone; hypertension; autoimmune disease;
KW heart failure.
XX
OS Rattus sp.
XX
PN WO200144475-A1.
XX
PD 21-JUN-2001.

```

XX 15-DEC-2000; 2000WO-JP08896.
PF 17-DEC-1999; 99JP-0358707.
PR 18-FEB-2000; 2000JP-0046825.
XX (TAKE) TAKEDA CHEM IND LTD.
PA
XX Hinuma S, Fukusumi S, Fujii R, Hosoya M;
PI WPI: 2001-408485/43.
DR N-PSDB: AAH46593.
XX polypeptides for treatment of hypertension, autoimmune disease and
PT heart failure -
XX Claim 2; Page 102-103; 107pp; Japanese.
XX The invention relates to a novel polypeptide comprising a fully defined
CC 130 amino acid sequence given in the specification and its amides,
CC esters and salts. The polypeptide has anterior pituitary hormone-related
CC activity. It is useful for the treatment of hypertension, autoimmune
CC diseases and heart failure. The screening method and kit also
CC provided in the invention are useful for identifying new substances
CC for treating and preventing these diseases. The present sequence is
CC is a polypeptide provided in the specification.
XX Sequence 129 AA:
SQ

Query Match

Best Local Similarity 85.2%; Score 615.5; DB 22; Length 129;
Matches 111; Conservative 8; Mismatches 10; Indels 1; Gaps 1;

OY 1 MKLAFLECPMALLLAGYGVLAGSSNLRFFVGCAVREFTFLAKKPGCGRLRTTAC 60
111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 :
DB 1 MKLIVYLAL-TAALLIGSDSVLSSSSGNLHFEVGCAREFTFAKKPGCGRLRTTAC 59
OY 61 WGRCEWEPILIEPPYIEAHRYCTYNETKQVTKLPNCAPGVDPFTYTPVAIRCCGAC 120
111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 :
DB 60 WGRCEWEPILIEPPYIEAHRYCTYNETKQVTKLPNCAPGVDPFTYTPVAIRCCGAC 119
OY 121 STATECEETI 130
111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 :
DB 120 STATECEETI 129

RESULT 6

AAG64065

ID AAG64065 standard; Protein; 106 AA.

XX AAG64065;

DT 17-SEP-2001 (first entry)

XX Human anterior pituitary hormone-related polypeptide #2.

XX Human; anterior pituitary hormone; hypertension; autoimmune disease;

KM heart failure.

XX Homo sapiens.

XX WO200144475-A1.

PD 21-JUN-2001.

PF 15-DEC-2000; 2000WO-JP08896.

PR 17-DEC-1999; 99JP-0358707.

XX 18-FEB-2000; 2000JP-0046825.

PA (TAKE) TAKEDA CHEM IND LTD.

XX Hinuma S, Fukusumi S, Fujii R, Hosoya M;

XX WPI: 2001-408485/43.
DR N-PSDB: AAH46589.
XX polypeptides for treatment of hypertension, autoimmune disease and
PT heart failure -
XX Claim 3; Page 100; 107pp; Japanese.
XX The invention relates to a novel polypeptide comprising a fully defined
CC 130 amino acid sequence given in the specification and its amides,
CC esters and salts. The polypeptide has anterior pituitary hormone-related
CC activity. It is useful for the treatment of hypertension, autoimmune
CC diseases and heart failure. The screening method and kit also
CC provided in the invention are useful for identifying new substances
CC for treating and preventing these diseases. The present sequence is
CC is a polypeptide of the invention.
XX Sequence 106 AA:
SQ

Query Match

Best Local Similarity 83.1%; Score 600; DB 22; Length 106;
Matches 106; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 25 ASSGNLRFTVGCAREFTFLAKKPGCGRLRTTACWGRCEWEPILIEPPYIEAHRYC 84
1 ASSGNLRFTVGCAREFTFLAKKPGCGRLRTTACWGRCEWEPILIEPPYIEAHRYC 60
DB 1 ASSGNLRFTVGCAREFTFLAKKPGCGRLRTTACWGRCEWEPILIEPPYIEAHRYC 60
OY 85 TYNETKQVTKLPNCAPGVDPFTYTPVAIRCCGACSTATECEETI 130
111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 : 111 :
DB 61 TYNETKQVTKLPNCAPGVDPFTYTPVAIRCCGACSTATECEETI 106

RESULT 7

AAG64068

ID AAG64068 standard; Protein; 106 AA.

XX AAG64068;

DT 17-SEP-2001 (first entry)

XX Rat anterior pituitary hormone-related polypeptide #2.

XX Rat; anterior pituitary hormone; hypertension; autoimmune disease;

KM heart failure.

XX Rattus sp.

XX WO200144475-A1.

PD 21-JUN-2001.

PF 15-DEC-2000; 2000WO-JP08896.

PR 17-DEC-1999; 99JP-0358707.

XX 18-FEB-2000; 2000JP-0046825.

PA (TAKE) TAKEDA CHEM IND LTD.

XX Hinuma S, Fukusumi S, Fujii R, Hosoya M;

PI WPI: 2001-408485/43.

DR N-PSDB: AAH46594.

XX polypeptides for treatment of hypertension, autoimmune disease and

PT heart failure -

XX Claim 4; Page 104; 107pp; Japanese.

XX The invention relates to a novel polypeptide comprising a fully defined
CC 130 amino acid sequence given in the specification and its amides,
CC esters and salts. The polypeptide has anterior pituitary hormone-related
CC activity. It is useful for the treatment of hypertension, autoimmune

Query Match	29.1%	Score 210:	DB 22:	Length 141:
Best Local Similarity	38.4%:	Pred. No.	9.2e-15:	
Matches 48:	Conservative 21:	Mismatches 46:	Indels 10:	Gaps 5:
OY	6 LFLGMAILLAGVCGVGASSGNIRTVGCACVFETLAKPGGR-GIRITTDACWGRC	64	:	:
	: : : : :	:	:	:

XX AAR15106;
 AC 11-FEB-1992 (first entry)
 DT hCG/bLH chimera, D10.
 DE
 XX
 KW Glycoprotein hormone; immuno-castration;
 KW immuno-contragestive; vaccine; human chorionic gonadotropin;
 KW luteinizing hormone; LH; CG; bovine.
 XX
 OS Homo sapiens.
 XX Bos taurus.
 PN KO9116922-A.
 PD 14-NOV-1991.
 XX
 PF 07-MAY-1991; 91WO-US03162.
 XX
 PR 08-MAY-1990; 90US-0520703.
 XX
 PA (UYNE-) UNIV MED NEW JERSEY.
 XX
 PI Campbell RK, Moyle WR;
 XX
 DR WPI; 1991-353528/48.
 XX
 PT New glyco-protein hormone analogues - for inducing fertility as
 PT immuno-castration agents, for suppressing reproductive system
 PT development and as immuno-contragestive vaccines.
 XX
 PS Table IV; Page 63; 94pp; English.
 XX
 CC The sequence is an analogue of mature hCG beta subunit having
 CC several residues replaced by the corresponding residues in the
 CC bovine LH protein. The chimeric hormone may be useful for identify-
 CC ing residues which are important for binding to the human receptor
 CC and may also have applications as an immunogen, agonist and/or
 CC antagonist.
 CC See AAR15043, AAR15061-R15125 and AAR15161-R15198.
 CC
 XX
 SQ Sequence 145 AA;
 Query Match 27.3%; Score 197; DB 12; Length 145;
 Best Local Similarity 39.0%; Pred. No. 2.4e-13;
 Matches 41; Conservative 18; Mismatches 38; Indels 8; Gaps 4;
 Oy 26 SSGNLRRTVGCAVREFFLAKKPGCR-GLRITTDACWGRCETWEK--PILPEPYIEAHNR 82
 Db 1 SRGPIRLPL--COPINATILAEKEKACPCVITFTTSTICAGYCSMKRVLLPMPQ---R 55
 Oy 83 VCTYNETKQVTVKLPNCAPGVDPFYTPVAIRCDGACSTATTEC 127
 Db 56 VCTYHELFASVRLPGCPGVDPWVSFPVALSCHGCPRLSLSTDC 100
 RESULT 13
 AAM47027
 ID AAM47027 standard; protein; 131 AA.
 AC AAM47027;
 XX
 DT 11-MAY-1998 (first entry)
 DE
 XX
 DE eCG hormone beta-subunit variant (1-131 amino acid residues).
 KW Equine; chorionic gonadotropin; hormone; eCG; beta-subunit; treatment;
 KW follicle-stimulating hormone; FSH; luteinizing hormone; LH; ovulation;
 KW ovarian disease; variant.
 XX
 OS Family Equidae.
 OS Synthetic.

XX Key Location/Qualifiers
 FH Peptide 1..20
 FT "note=" "signal peptide"
 FT Protein 21..131
 FT "note=" "mature protein"
 XX
 PN JP10036399-A.
 XX
 PD 10-FEB-1998.
 XX
 PE 24-JUL-1996; 96JP-0212197.
 XX
 PR 24-JUL-1996; 96JP-0212197.
 XX
 PA (ELED) DENKI KAGAKU KOGYO KK.
 XX
 DR WPI; 1998-174916/16.
 XX
 PT Recombinant truncated equine chorionic gonadotropin hormone - has
 PT enhanced follicle stimulating hormone activity and reduced
 PT luteinizing hormone activity; useful as ovulation inducer
 XX
 PS Claim 7; Page -: 16pp; Japanese.
 CC
 CC This is a variant of the beta-subunit of an equine chorionic gonadotropin
 CC (eCG) hormone. The variants are created by removing 39 or lesser amino
 CC acid residues from the C-terminal peptide region of the beta-subunit. The
 CC recombinant eCG hormone is composed of alpha-subunit and the variant
 CC beta-subunits of eCG hormone and has a substantially enhanced follicle-
 CC stimulating hormone (FSH) activity and reduced luteinizing hormone (LH)
 CC activity. The hormone is an ovulation inducer and can be used as an
 CC agent for the treatment of ovarian diseases.
 CC Note: This sequence does not appear in the specification. It has been
 CC created by modifying the eCG beta-subunit sequence provided in page 11.
 CC
 XX
 SQ Sequence 131 AA;
 Query Match 25.4%; Score 183.5; DB 19; Length 131;
 Best Local Similarity 35.5%; Pred. No. 5.9e-12;
 Matches 44; Conservative 15; Mismatches 48; Indels 17; Gaps 5;
 Oy 11 MALLIAGYGVYLGASGNLRTFVGCAVREFFLAKKPGCR-GLRITTDACWGRCETWEK 69
 Db 7 LILMMLISVGSV-WASRGPIRLPL--CRPINATILAEKEKACPICITFTTSTICAGYCSMYR 63
 Oy 70 -----PILPEPYIEAHNRCTYNETKQVTVKLPNCAPGVDPFYTPVAIRCDGACASTA 123
 Db 64 VMPALPLAIPGP-----VCTYRELRFASIRLPGCPGVDPWVSFPVALSCHGCPQIQIK 116
 Oy 124 TTEC 127
 Db 117 TTDG 120
 RESULT 14
 AAM47025
 ID AAM47025 standard; protein; 134 AA.
 AC AAM47025;
 XX
 DT 11-MAY-1998 (first entry)
 DE
 XX
 DE eCG hormone beta-subunit variant (1-134 amino acid residues).
 KW Equine; chorionic gonadotropin; hormone; eCG; beta-subunit; treatment;
 KW follicle-stimulating hormone; FSH; luteinizing hormone; LH; ovulation;
 KW ovarian disease; variant.
 XX
 OS Family Equidae.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers

```

FT Peptide 1..20
FT /note= "signal peptide"
FT Protein 21..134
FT /note= "mature protein"
PN JP10036399-A.
XX
XX 10-FEB-1998.
XX
XX 24-JUL-1996; 96JP-0212197.
XX
XX 24-JUL-1996; 96JP-0212197.
XX
XX (ELED ) DENKI KAGAKU KOGYO KK.
XX
XX WPI; 1998-174916/16.
XX
XX PT Recombinant truncated equine chorionic gonadotropin hormone - has
XX PT enhanced follicle-stimulating hormone activity and reduced
XX PT luteinising hormone activity; useful as ovulation inducer
XX
XX PS Claim 6; Page -: 16pp; Japanese.
XX
XX CC This is a variant of the beta-subunit of an equine chorionic gonadotropin
XX CC (eCG) hormone. The variants are created by removing 39 or lesser amino
XX CC acid residues from the C-terminal peptide region of the beta-subunit. The
XX CC recombinant eCG hormone is composed of alpha-subunit and the variant
XX CC beta-subunits of eCG hormone and has a substantially enhanced follicle-
XX CC stimulating hormone (FSH) activity and reduced luteinising hormone (LH)
XX CC activity. The hormone is an ovulation inducer and can be used as an
XX CC agent for the treatment of ovarian diseases.
XX CC Note: This sequence does not appear in the specification. It has been
XX CC created by modifying the eCG beta-subunit sequence provided in Page 11.
XX
SQ Sequence 134 AA:
Query Match 25.4%; Score 183.5; DB 19; Length 134;
Best Local Similarity 35.5%; Pred. No. 6e-12;
Matches 44; Conservative 15; Mismatches 48; Indels 17; Gaps 5;
QY 11 MALLLAGYGVGASSGNLRTFVGCAVREFTFLAKKPGCR-GLRTITDCAWGRCEETWEK 69
DB 7 LLLMMLLSVGV-WASRGPLRL--CRPINATLAERKACPCITFTTSICAGYCSWVR 63
QY 70 -----PILEPPYIEAHHRVCTYNETKQYVTKLPNCAPGVDPYTYTPVAIRCDGACSTA 123
DB 64 VMPAALPAIPQP-----VCTYRELRFASIRLPGCPGVDPWVSPVALSCHGCPQIQR 116
QY 124 TTEC 127
DB 117 TTDC 120

```

RESULT 15
AAW47026
ID AAW47026 standard; protein; 137 AA.
XX
AC AAW47026;
XX
XX 11-MAY-1998 (first entry)
XX
XX eCG hormone beta-subunit variant (1-137 amino acid residues).
XX
XX Equine; chorionic gonadotropin; hormone; eCG; beta-subunit; treatment;
XX KW follicle-stimulating hormone; FSH; luteinising hormone; LH; ovulation;
XX KM ovarian disease; variant.
XX
XX Family Equidae.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX FH Peptide 1..20
XX /note= "signal peptide"

```

FT Protein 21..137
FT /note= "mature protein"
PN JP10036399-A.
XX
XX 10-FEB-1998.
XX
XX 24-JUL-1996; 96JP-0212197.
XX
XX 24-JUL-1996; 96JP-0212197.
XX
XX (ELED ) DENKI KAGAKU KOGYO KK.
XX
XX WPI; 1998-174916/16.
XX
XX PT Recombinant truncated equine chorionic gonadotropin hormone - has
XX PT enhanced follicle-stimulating hormone activity and reduced
XX PT luteinising hormone activity; useful as ovulation inducer
XX
XX PS Claim 8; Page -: 16pp; Japanese.
XX
XX CC This is a variant of the beta-subunit of an equine chorionic gonadotropin
XX CC (eCG) hormone. The variants are created by removing 39 or lesser amino
XX CC acid residues from the C-terminal peptide region of the beta-subunit. The
XX CC recombinant eCG hormone is composed of alpha-subunit and the variant
XX CC beta-subunits of eCG hormone and has a substantially enhanced follicle-
XX CC stimulating hormone (FSH) activity and reduced luteinising hormone (LH)
XX CC activity. The hormone is an ovulation inducer and can be used as an
XX CC agent for the treatment of ovarian diseases.
XX CC Note: This sequence does not appear in the specification. It has been
XX CC created by modifying the eCG beta-subunit sequence provided in Page 11.
XX
SQ Sequence 137 AA:
Query Match 25.4%; Score 183.5; DB 19; Length 137;
Best Local Similarity 35.5%; Pred. No. 6.2e-12;
Matches 44; Conservative 15; Mismatches 48; Indels 17; Gaps 5;
QY 11 MALLLAGYGVGASSGNLRTFVGCAVREFTFLAKKPGCR-GLRTITDCAWGRCEETWEK 69
DB 7 LLLMMLLSVGV-WASRGPLRL--CRPINATLAERKACPCITFTTSICAGYCSWVR 63
QY 70 -----PILEPPYIEAHHRVCTYNETKQYVTKLPNCAPGVDPYTYTPVAIRCDGACSTA 123
DB 64 VMPAALPAIPQP-----VCTYRELRFASIRLPGCPGVDPWVSPVALSCHGCPQIQR 116
QY 124 TTEC 127
DB 117 TTDC 120

```

Search completed: October 11, 2002, 08:22:44
Job time : 33 secs